PortfoliosLab logoPortfoliosLab logo
TATYY vs. AZN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

TATYY vs. AZN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tate & Lyle PLC ADR (TATYY) and AstraZeneca PLC (AZN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, TATYY achieves a 33.17% return, which is significantly higher than AZN's -2.12% return. Over the past 10 years, TATYY has underperformed AZN with an annualized return of 2.20%, while AZN has yielded a comparatively higher 14.81% annualized return.


TATYY

1D
0.97%
1M
33.30%
YTD
33.17%
6M
38.15%
1Y
-6.81%
3Y*
-8.77%
5Y*
-3.37%
10Y*
2.20%

AZN

1D
-0.66%
1M
-3.91%
YTD
-2.12%
6M
-0.95%
1Y
26.16%
3Y*
9.19%
5Y*
11.73%
10Y*
14.81%
*Multi-year figures are annualized to reflect compound growth (CAGR)

TATYY vs. AZN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
TATYY
Tate & Lyle PLC ADR
33.17%-35.21%-0.61%-0.36%18.05%-0.65%-1.93%19.27%-4.33%9.74%
AZN
AstraZeneca PLC
-2.12%43.30%-0.62%1.44%19.14%19.66%3.12%35.68%13.86%33.10%

Correlation

The correlation between TATYY and AZN is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.14

Correlation (3Y)
Calculated over the trailing 3-year period

0.14

Correlation (5Y)
Calculated over the trailing 5-year period

0.11

Correlation (10Y)
Calculated over the trailing 10-year period

0.11

Correlation (All Time)
Calculated using the full available price history since Jan 5, 2016

0.12

Fundamentals

Market Cap

TATYY:

$3.02B

AZN:

$275.17B

EPS

TATYY:

$2.15

AZN:

$6.66

PE Ratio

TATYY:

12.53

AZN:

26.48

PS Ratio

TATYY:

0.85

AZN:

4.55

PB Ratio

TATYY:

1.89

AZN:

5.81

Total Revenue (TTM)

TATYY:

$3.54B

AZN:

$60.44B

Gross Profit (TTM)

TATYY:

$722.00M

AZN:

$49.37B

EBITDA (TTM)

TATYY:

$597.20M

AZN:

$20.47B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

TATYY vs. AZN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TATYY
TATYY Risk / Return Rank: 3636
Overall Rank
TATYY Sharpe Ratio Rank: 3636
Sharpe Ratio Rank
TATYY Sortino Ratio Rank: 3636
Sortino Ratio Rank
TATYY Omega Ratio Rank: 3737
Omega Ratio Rank
TATYY Calmar Ratio Rank: 3636
Calmar Ratio Rank
TATYY Martin Ratio Rank: 3737
Martin Ratio Rank

AZN
AZN Risk / Return Rank: 7070
Overall Rank
AZN Sharpe Ratio Rank: 7272
Sharpe Ratio Rank
AZN Sortino Ratio Rank: 7070
Sortino Ratio Rank
AZN Omega Ratio Rank: 6565
Omega Ratio Rank
AZN Calmar Ratio Rank: 7171
Calmar Ratio Rank
AZN Martin Ratio Rank: 7474
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TATYY vs. AZN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Tate & Lyle PLC ADR (TATYY) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


TATYYAZNDifference
Sharpe ratioReturn per unit of total volatility

-1.17

Sortino ratioReturn per unit of downside risk

-1.51

Omega ratioGain probability vs. loss probability

1.03

1.20

-0.17

Calmar ratioReturn relative to maximum drawdown

-0.17

1.71

-1.88

Martin ratioReturn relative to average drawdown

-0.26

4.70

-4.96

TATYY vs. AZN - Sharpe Ratio Comparison

The current TATYY Sharpe Ratio is -0.12, which is lower than the AZN Sharpe Ratio of 1.05. The chart below compares the historical Sharpe Ratios of TATYY and AZN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


TATYYAZNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.12

1.05

-1.17

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.09

0.49

-0.58

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.07

0.60

-0.53

Sharpe Ratio (All Time)

Calculated using the full available price history

0.08

0.49

-0.41

Drawdowns

TATYY vs. AZN - Drawdown Comparison

The maximum TATYY drawdown since its inception was -57.06%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for TATYY and AZN.


Loading charts...

Drawdown Indicators


TATYYAZNDifference

Max Drawdown

Largest peak-to-trough decline

-57.06%

-48.94%

-8.12%

Max Drawdown (1Y)

Largest decline over 1 year

-40.33%

-15.43%

-24.90%

Max Drawdown (3Y)

Largest decline over 3 years

-57.06%

-27.87%

-29.19%

Max Drawdown (5Y)

Largest decline over 5 years

-57.06%

-27.87%

-29.19%

Max Drawdown (10Y)

Largest decline over 10 years

-57.06%

-27.87%

-29.19%

Current Drawdown

Current decline from peak

-34.42%

-15.43%

-18.99%

Average Drawdown

Average peak-to-trough decline

-15.55%

-11.37%

-4.18%

Ulcer Index

Depth and duration of drawdowns from previous peaks

26.04%

5.60%

+20.44%

Volatility

TATYY vs. AZN - Volatility Comparison

Tate & Lyle PLC ADR (TATYY) has a higher volatility of 37.59% compared to AstraZeneca PLC (AZN) at 6.36%. This indicates that TATYY's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


TATYYAZNDifference

Volatility (1M)

Calculated over the trailing 1-month period

37.59%

6.36%

+31.23%

Volatility (6M)

Calculated over the trailing 6-month period

43.04%

17.06%

+25.98%

Volatility (1Y)

Calculated over the trailing 1-year period

55.80%

25.18%

+30.62%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

37.69%

23.94%

+13.75%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

33.91%

24.90%

+9.01%

Dividends

TATYY vs. AZN - Dividend Comparison

TATYY's dividend yield for the trailing twelve months is around 3.96%, more than AZN's 3.02% yield.


PositionTTM20252024202320222021202020192018201720162015
AZN
AstraZeneca PLC
3.02%1.70%2.27%2.15%2.12%2.35%2.80%2.81%3.69%3.95%5.01%4.06%
TATYY
Tate & Lyle PLC ADR
3.96%5.27%3.03%2.90%19.44%4.72%3.74%3.67%4.18%3.64%3.81%0.00%

Financials

TATYY vs. AZN - Financials Comparison

This section allows you to compare key financial metrics between Tate & Lyle PLC ADR and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20222023202420252026
996.75M
15.29B
(TATYY) Total Revenue
(AZN) Total Revenue
Values in USD except per share items

TATYY vs. AZN - Profitability Comparison

The chart below illustrates the profitability comparison between Tate & Lyle PLC ADR and AstraZeneca PLC over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%202220232024202520260
82.5%
Portfolio components
TATYY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Tate & Lyle PLC ADR reported a gross profit of 0.00 and revenue of 996.75M. Therefore, the gross margin over that period was 0.0%.

AZN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.

TATYY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Tate & Lyle PLC ADR reported an operating income of 83.23M and revenue of 996.75M, resulting in an operating margin of 8.4%.

AZN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.

TATYY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Tate & Lyle PLC ADR reported a net income of 41.62M and revenue of 996.75M, resulting in a net margin of 4.2%.

AZN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.


Frequently Asked Questions


TATYY and AZN have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

TATYY has higher volatility (37.59%) compared to AZN (6.36%). In terms of maximum drawdown, TATYY dropped -57.06% vs AZN's -48.94%.

AZN currently has the higher Sharpe Ratio (1.05 vs -0.12), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for TATYY and AZN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer